Gritstone Oncology is committed to providing the media with accurate and timely information.
Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA (pMHC) complexes, today announced the issuance of two patents in 2025 expanding the company’s international intellectual property portfolio.
Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA complexes, today announced its acceptance into MBC BioLabs, one of the Bay Area’s leading incubators for early-stage life science companies.